Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis

Xu, Xiangbo; Guo, Xiaozhong; Stefano, Valerio De; Silva‐Junior, Gilberto; Goyal, Hemant; Bai, Zhaohui; Zhao, Qingchun; Qi, Xingshun

doi:10.1007/s12072-019-09951-6

Cited by 50 publications

(41 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonselective b-blockers (NSBBs), including propranolol and nadolol, which are generally recommended for the primary and secondary prophylaxis of esophageal variceal bleeding in cirrhotic patients [12][13][14], can significantly decrease the portal vein velocity [15][16][17]. Thus, we hypothesized that NSBBs might induce the development of PVT [18], and our recent meta-analysis confirmed this association [19]. However, due to its benefits in decreasing the risk of bleeding and death, the long-term use of NSBBs remains necessary.…”

Section: Introductionmentioning

confidence: 88%

Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study

Primignani

et al. 2020

Adv Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 88%

Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study

Primignani

et al. 2020

Adv Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nonselective β-blockers (NSBB) reduce PBFV by decreasing cardiac output and promoting splanchnic vasoconstriction, 22 and a recent meta-analysis 23 has suggested that NSBB may have a role in PVT formation. However, most of the studies included were retrospective and did not take into account other factors potentially influencing PVT development, such as variceal bleeding or the presence and size of esophageal varices, and did not consider new prescription or withdrawal of NSBB during follow-up.…”

Section: Other Risk Factorsmentioning

confidence: 99%

New Insights into the Pathogenesis, Risk Factors, and Treatment of Portal Vein Thrombosis in Patients with Cirrhosis

Nicoară-Farcău

Soy

Magaz

et al. 2020

Semin Thromb Hemost

View full text Add to dashboard Cite

Portal vein thrombosis (PVT) is a frequent event in patients with cirrhosis regardless of etiology. Notwithstanding the commonality of the problem, the pathophysiology and risk factors for PVT in cirrhosis are largely unknown. The clinical impact of PVT in the natural history of cirrhosis is unclear, indications for PVT treatment are not well defined, and treatment recommendations are based on experts' opinion and consensus only. Therefore, this review aims to summarize current knowledge of mechanisms and risk factors for PVT development and assess the current evidence of PVT management, with a special focus on strategies of anticoagulation and transjugular intrahepatic portosystemic shunt placement.

show abstract

“…21,22 Fourth, the use of NSBBs is also considered as a risk factor for the development of portal vein thrombosis. 23,24…”

Section: Introductionmentioning

confidence: 99%

Use of nonselective β blockers after variceal eradication in cirrhotic patients undergoing secondary prophylaxis of esophageal variceal bleeding: a critical review of current evidence

Guo

Tacke

et al. 2019

Therapeutic Advances in Chronic Disease

Self Cite

View full text Add to dashboard Cite

Nonselective β blockers (NSBBs) combined with esophageal variceal ligation (EVL) are recommended for secondary prophylaxis of esophageal variceal bleeding (EVB) in cirrhotic patients according to the current practice guidelines and consensus. However, until now, there is a paucity of recommendations regarding the use of NSBBs in cirrhotic patients who achieved variceal eradication. In this review paper, we firstly introduced a case who achieved variceal eradication after additional use of NSBBs for secondary prophylaxis of EVB and then did not require further endoscopic therapy during repeated endoscopic surveillance, and subsequently discuss the importance of NSBBs for secondary prophylaxis of EVB, the effect of NSBBs after variceal eradication, adherence to NSBBs, screening for variceal recurrence, and timing of endoscopic surveillance after variceal eradication.

show abstract

Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis

Cited by 50 publications

References 48 publications

Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study

Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study

New Insights into the Pathogenesis, Risk Factors, and Treatment of Portal Vein Thrombosis in Patients with Cirrhosis

Use of nonselective β blockers after variceal eradication in cirrhotic patients undergoing secondary prophylaxis of esophageal variceal bleeding: a critical review of current evidence

Contact Info

Product

Resources

About